Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and...

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Newly diagnosed multiple myeloma (MM) patients typically receive VRD induction, autologous stem cell transplantation (autoHCT), and lenalidomide maintenance.
• Most MM patients eventually relapse and require second-line (2L) therapy.
• Identifying effective 2L treatments is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the effectiveness of different second-line (2L) therapies in multiple myeloma (MM) patients.
• To compare outcomes for patients receiving daratumumab-based regimens versus other 2L treatments.
• To identify factors associated with improved progression-free survival (PFS2) and overall survival (OS).

Main Methods:

• Retrospective, single-center study of 146 multiple myeloma (MM) patients.
• Patients received VRD induction, autoHCT, and lenalidomide maintenance prior to relapse.
• Analysis of 2L therapy choices including immunomodulatory drug (IMiD) + proteasome inhibitor (PI) triplets/doublets and daratumumab (Dara)-based regimens.

Main Results:

• Daratumumab (Dara)-based 2L therapy achieved significantly higher very good partial response (≥VGPR) rates (63%) compared to IMiD+PI triplets (35%) or doublets (34%).
• Median PFS2 was substantially longer with Dara-based regimens (59.9 months) versus other regimens (12.3-11.5 months).
• Multivariable analysis confirmed Dara-based therapy was associated with improved PFS2, while clinical progression predicted worse outcomes.

Conclusions:

• Daratumumab-based second-line regimens demonstrate superior efficacy in multiple myeloma, significantly extending PFS2.
• These findings support the use of daratumumab-containing therapies as an effective 2L treatment option for relapsed MM.
• Further research may explore optimal sequencing and combination strategies involving daratumumab.